Evidence map›Paper›PMID 35440537›Full record

ArticleNature communications2022

A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea.

Jiezhou Pan, Guidong Gong, Qin Wang, Jiaojiao Shang, Yunxiang He, Chelsea Catania, Dan Birnbaum, Yifei Li, Zhijun Jia, Yaoyao Zhang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
21.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 273 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Microbiology spectrum · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Nanozymes-Armed ProbioticResearch (Washington, D.C.) · 2026
    Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Jiezhou Pan *BMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China.
Guidong Gong *BMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China.ORCID http://orcid.org/0000-0002-1276-6287
Qin WangSchool of Pharmacy, Southwest Minzu University, Chengdu, Sichuan, 610065, China.
Jiaojiao ShangBMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China.
Yunxiang HeBMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China.ORCID http://orcid.org/0000-0001-5275-2691
Chelsea CataniaDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0002-7222-6194
Dan BirnbaumWyss Institute for Biologically Inspired Engineering, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Yifei LiBMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China.ORCID http://orcid.org/0000-0002-3096-4287
Zhijun JiaBMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China.
Yaoyao ZhangBMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China. zhangyaoyao@hsc.pku.edu.cn.ORCID http://orcid.org/0000-0001-8443-3636
Neel S JoshiWyss Institute for Biologically Inspired Engineering, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA. ne.joshi@northeastern.edu.ORCID http://orcid.org/0000-0001-8236-3566
Junling GuoBMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610065, China. junling.guo@scu.edu.cn.ORCID http://orcid.org/0000-0002-2948-880X
Sichuan University · CNHarvard University · USMassachusetts Institute of Technology · USNortheastern University · USSouthwest Minzu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota represents a large community of microorganisms that play an important role in immune regulation and maintenance of homeostasis. Living bacteria receive increasing interest as potential therapeutics for gut disorders, because they inhibit the colonization of pathogens and positively regulate the composition of bacteria in gut. However, these treatments are often accompanied by antibiotic administration targeting pathogens. In these cases, the efficacy of therapeutic bacteria is compromised by their susceptibility to antibiotics. Here, we demonstrate that a single-cell coating composed of tannic acids and ferric ions, referred to as 'nanoarmor', can protect bacteria from the action of antibiotics. The nanoarmor protects both Gram-positive and Gram-negative bacteria against six clinically relevant antibiotics. The multiple interactions between the nanoarmor and antibiotic molecules allow the antibiotics to be effectively absorbed onto the nanoarmor. Armored probiotics have shown the ability to colonize inside the gastrointestinal tracts of levofloxacin-treated rats, which significantly reduced antibiotic-associated diarrhea (AAD) resulting from the levofloxacin-treatment and improved some of the pre-inflammatory symptoms caused by AAD. This nanoarmor strategy represents a robust platform to enhance the potency of therapeutic bacteria in the gastrointestinal tracts of patients receiving antibiotics and to avoid the negative effects of antibiotics in the gastrointestinal tract.

Indexed as

Anti-Bacterial AgentsProbioticsAnimalsBacteriaDiarrheaGram-Negative BacteriaGram-Positive BacteriaHumansLevofloxacinRatsAnti-Bacterial AgentsLevofloxacin

Identifiers

PMID35440537
PMCPMC9019008
OpenAlexW4224267221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.